In a world full of tough competitors, if a company can hardly survive if it doesn’t focus on innovation. EKSO BIONICS HOLDING (OTCBB:EKSO) is one such company, which doesn’t want to include its name in the list of failed ones. In order to make sure that it can innovate its way of working, Ekso has decided to launch a multicenter study with some of the largest European hospitals. As per the reports, nine hospitals have given their approval to participate in this study as of now.
Insights On The Study:
Ekso is a well known robotic exoskeleton company, which focuses on innovation and perfection in the first place. The company has tied up with nine leading medical centers that include names like PZ Notwill in Switzerland, Clinic for Spinal Cord Injuries in Hornbaek, Denmark, and Institut Guttmann in Spain. The primary agenda of this program is to run a clinical study that will include around 70 participants.
It will examine as how can Ekso improve the outcomes and decrease secondary components such as bowel, pain and bladder dysfunction concerning spinal cord injury. As per the reports, this study will run for 30 months, but the company expects that it will reach rightful findings by early 2016. The senior management of the company calls it an innovative step, which will affect the world in the coming days.
While giving an interview, Chief Communication Officer and President of EKSO BIONICS HOLDING (OTCBB:EKSO), Thomas Looby stated that it was the first study with such long vision and outputs that will positively affect the world, in the long run. The initial results of this study have come out positive, which has motivated the entire management team to take this study to all new level by taking charge in compelling dataset across different clinical environments and treatment protocols.
All the medical institutes which have decided to shake hands with Ekso are very prominent in their fields and expected to help the company in achieving what nobody could do in the past.